<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35583664</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-6143</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</Title>
          <ISOAbbreviation>Am J Transplant</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the Omicron surge.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ajt.17098</ELocationID>
        <Abstract>
          <AbstractText>The SARS-CoV-2 pandemic continues to place a substantial burden on healthcare systems. Outpatient therapies for mild-to-moderate disease have reduced hospitalizations and deaths in clinical trials, but the real-world effectiveness of monoclonal antibodies and oral antiviral agents in solid organ transplant recipients (SOTR) with COVID-19 is largely uncharacterized. We conducted a single-center, retrospective review of 122 SOTR diagnosed with COVID-19 in the outpatient setting during the Omicron surge to address this knowledge gap. The mean age was 54 years, 57% were males, and 67% were kidney transplant recipients. The mean time from transplant to COVID-19 diagnosis was 75 months. Forty-nine (40%) received molnupiravir, 24 (20%) received sotrovimab, and 1 (0.8%) received nirmatrelvir/ritonavir. No outpatient therapy was administered in 48 (39%). All 122 SOTR had &gt;30 days follow-up. Rates of hospitalization within 30 days of initiating therapy for molnupiravir, nirmatrelvir/ritonavir, and sotrovimab were 16% (8/49), 0% (0/1), and 8% (2/24), respectively, compared to 27% (13/48) in patients without outpatient therapy. There were no deaths in those who received any therapy versus 3 (6%) deaths in patients without outpatient therapy (p=0.002). Overall, our experience suggests a role for monoclonal antibodies and oral antiviral agents in reducing COVID-19-related morbidity and mortality in SOTR.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Radcliffe</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palacios</LastName>
            <ForeName>Carlo Foppiano</ForeName>
            <Initials>CF</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Azar</LastName>
            <ForeName>Marwan M</ForeName>
            <Initials>MM</Initials>
            <Identifier Source="ORCID">0000-0001-5498-5042</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0001-7853-4107</Identifier>
            <AffiliationInfo>
              <Affiliation>Yale New Haven Transplant Center, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malinis</LastName>
            <ForeName>Maricar</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-5720-9994</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Transplant</MedlineTA>
        <NlmUniqueID>100968638</NlmUniqueID>
        <ISSNLinking>1600-6135</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">molnupiravir</Keyword>
        <Keyword MajorTopicYN="N">nirmatrelvir</Keyword>
        <Keyword MajorTopicYN="N">solid organ transplant</Keyword>
        <Keyword MajorTopicYN="N">sotrovimab</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>11</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35583664</ArticleId>
        <ArticleId IdType="doi">10.1111/ajt.17098</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
